-
2021 EHA Discovery of New Drugs for Multiple Myeloma
Time of Update: 2021-06-17
The study shows that RRMM patients (including daratumomab and bortezomib refractory patients) who have undergone multi-line therapy in the past receive IberDd, IberVd and IberKd treatments with controllable safety and considerable efficacy .
-
Jalova, a new generation of CD20 monoclonal antibody, was approved for marketing, innovating the first-line treatment standard for follicular lymphoma
Time of Update: 2021-06-17
5 months, compared with the standard treatment regimen in the control group, the combination of otuzumab chemotherapy can significantly reduce the risk of progression/recurrence or death by 34%, and a progression-free survival period Significantly prolonged (three-year PFS rate was 80.
-
ASCO first-line treatment of specific non-small cell lung cancer, Novartis announces overall survival data for MET inhibitors
Time of Update: 2021-06-17
▎The content team editor of WuXi AppTec recently, at the American Society of Clinical Oncology (ASCO) in 2021, Novartis announced the oral high-selective small molecule MET inhibitor Tabrecta (capmatinib) for the treatment of metastatic non-small cell lung cancer (NSCLC) The latest Phase 2 clinical trial data for adult patients .
-
Express treatment of HER2-positive breast cancer patients, a new generation of ADC reaches the phase 3 clinical endpoint
Time of Update: 2021-06-17
▎ WuXi AppTec content team editor June 8, 2021, Byondis announced that its new generation of antibody conjugate (ADC) trastuzumab duocarmazine (SYD985) has achieved progression-free survival (PFS) in the Phase 3 clinical study TULIP The main end point .
-
Esophageal Squamous Cell Carcinoma (ESCC) Immunotherapy!
Time of Update: 2021-06-17
Compared with chemotherapy, Opdivo+chemotherapy, Opdivo+Yervoy in the patient population with tumor cell PD-L1 expression ≥1%, in all random patient populations, make OS have a statistically significant and clinically significant improvement in tumors The specific data are as follows: (1) Among patients with tumors expressing PD-L1, the median OS of the 1Opdivo+ chemotherapy group was 15.
-
The clinical data of KN046 combined with chemotherapy in the first-line treatment of pancreatic cancer will be released in ASCO 2021
Time of Update: 2021-06-17
As of January 15, 2021, 9 patients received at least one tumor assessment and entered the efficacy analysis data set, and 17 patients entered the safety analysis data set . The objective response ra
-
Multiple clinical research data of dual antibodies KN046 and KN026 will be unveiled in ASCO 2021, covering multiple tumor types such as lung cancer and pancreatic cancer
Time of Update: 2021-06-17
*Only for medical professionals to read and reference. Recently, 3 clinical research data of KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented in the ASCO 2021 annual meeting in the form of
-
A cancer vaccine based on arenavirus vectors announces positive results in a phase 1 trial, and medical doctor Mai Meng broke the news for HPV 16-positive cancers
Time of Update: 2021-06-17
In the company’s oral report (Abstract #2502), it was mentioned that the phase 1 trial of HB-201 in the treatment of HPV16+ cancer patients showed that the immune response of T cells was outstanding.
-
Radiology: For children with tumors, don't always think about CT!
Time of Update: 2021-06-16
There is no significant difference between the maximum SUV change (100%; 95% CI: 99%, 100%) and the minimum ADC change (98%; 95% CI: 94%, 100%) in predicting clinical treatment responseIn summary, this study proves that whole-body diffusion-weighted MRI can help clinically evaluate the response of children's tumors, especially in lymphoma and sarcoma patients 8-12 weeks after starting treatment .
-
JNCI: Comparison of three PD-L1 immunohistochemical analysis methods and their correlation with the prognosis of triple-negative breast cancer patients
Time of Update: 2021-06-16
In the phase 3 IMpassion130 study, atezolizumab combined with nab-paclitaxel (A+nP) was positive for PD-L1 (tumor infiltrating immune cells [IC] ≥ 1%; SP142 immunohistochemistry [IHC]) late/metastatic Clinical benefits have been demonstrated in patients with triple negative breast cancer (TNBC) .
-
ASCO2021: Nivolumab + Ipilimumab can benefit patients with advanced NSCLC (4 years of data from CheckMate-227)
Time of Update: 2021-06-16
. The three-year overall survival (OS) data of this trial was announced at the 2020 ASCO annual meeting, showing that about one-third of PD-L1-positive and PD-L1-negative patients are still alive after receiving nivo+ipi for 3 years .
-
The role of tumor-derived exosomes in the differentiation, maturation and functional changes of dendritic cells
Time of Update: 2021-06-16
Recently, researchers at Isfahan Medical University in Iran published an article titled "The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells" in Molecular Cancer .
-
JNCCN: Comparison of different applications of radiotherapy and chemotherapy in elderly patients with local anal cancer
Time of Update: 2021-06-16
In summary, for I-III anal squamous cell carcinoma (SCCA), the proportion of elderly patients receiving SOC CRT is lower than that of non-elderly patients .
For I–III anal squamous cell carcinoma (SCCA), the proportion of elderly patients receiving SOC CRT is lower than that of non-elderly patients .
-
Consensus interpretation: The combined immune targeting program opens up a new direction for the transformational treatment of advanced hepatocellular carcinoma in my country!
Time of Update: 2021-06-16
1 ) Downgrade advanced tumors to obtain a chance for radical surgery; 2 ) When conversion therapy is effective but imaging follow-up does not benefit further, local treatment or surgical resection should be superimposed at appropriate time to eliminate the potential impact of tumor heterogeneity on prognosis .
-
ASCO2021 releases new recommendations on systemic therapeutic doses for obese adult cancer patients
Time of Update: 2021-06-16
The motivation for the update of this guideline is to include new data on the impact of doses on obese cancer patients, the benefits of full body weight doses, and any evidence on non-cytotoxic drugs (such as immunotherapy and targeted therapy) .
-
Nat Commun: RFC4/Notch1 positive feedback loop can promote the metastasis and stem cell characteristics of non-small cell lung cancer
Time of Update: 2021-06-16
The positive feedback loop between RFC4 and NICD1 plays a key role in the metastasis and stem cell characteristics of NSCLC, and reveals its diagnostic and prognostic potential in the treatment of NSCLC .
-
Radiology: Arm artificial intelligence with the thinking of a radiologist!
Time of Update: 2021-06-16
By using the accuracy of the top 1, top 2, and top 3 differential diagnosis on 92 independent test group patients (average age, 47 years ± 18; 52 women), and the radiologists, general radiologists, neurologists A radiology researcher and an academic neuroradiology expert were compared .
-
ASCO2021: Immune expression signals can predict treatment response and survival of metastatic colorectal cancer
Time of Update: 2021-06-16
Cleary agreed and said that this trial, as well as other studies presented at the ASCO annual meeting this year , and other recent studies indicate that RNA expression profiling and other molecular techniques may help identify patients for targeting And immunotherapy .
-
JCO: Clinicopathological characteristics of NRG1 fusion-positive lung cancer and its response to various treatments
Time of Update: 2021-06-16
NRG1 fusion-positive lung cancer patients treated with platinum-containing dual-drug and paclitaxel-based chemotherapy (after platinum dual-drug therapy) had lower objective response rates (ORRs were 13% and 14%, respectively), and median progression-free survival The period is average (PFS is 5.
-
Radiology: Application of multi-parameter MRI in preoperative prediction of extraprostatic invasion
Time of Update: 2021-06-16
Recently, a study published in the journal Radiology compared classification, European Society of Urology and Reproductive Society (ESUR) score, Likert scale, and capsular contact length (CCL) to evaluate and predict the diagnosis of EPE after radical resection of prostate cancer.
